Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

15.50 +0.20 (+1.31%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
Expert Ratings for Arcus Biosciences
Via Benzinga
Arcus Biosciences Return On Capital Employed Insights
  
Via Benzinga
Recap: Arcus Biosciences Q2 Earnings
Arcus Biosciences (NYSE:RCUS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:03 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Via Benzinga
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer
From Arcus Biosciences, Inc.
Via Business Wire
Analyst Ratings for Arcus Biosciences
Over the past 3 months, 4 analysts have published their opinion on Arcus Biosciences (NYSE:RCUS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update
From Arcus Biosciences, Inc.
Via Business Wire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
From Arcus Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.